Crispr Therapeutics shares tumble after significant earnings miss
Andrew Cappotelli, Senior Vice President of Operations at Paylocity Holding Corp (NASDAQ:PCTY), a $10.5 billion market cap company with impressive gross profit margins of nearly 69%, recently sold shares of the company in a transaction dated June 3, 2025. According to a Form 4 filing with the Securities and Exchange Commission, Cappotelli sold 10 shares of Paylocity stock at an average price of $190.34, totaling $1,903. This transaction was conducted under an approved 10b5-1 plan adopted by Cappotelli on September 17, 2024.
In a separate transaction on June 2, 2025, Cappotelli disposed of 52 shares at a price of $190.90, resulting in a total value of $9,926. Following these transactions, Cappotelli holds 13,670 shares of Paylocity stock.
In other recent news, Paylocity Holding Corp. reported its third-quarter earnings for 2025, surpassing Wall Street expectations. The company achieved an earnings per share (EPS) of $2.43, exceeding the forecasted $2.13, while revenue reached $454.55 million, surpassing the anticipated $442 million. Paylocity’s recurring and other revenue rose by 15% year-over-year to $421.1 million, reflecting its strategic focus on product innovation and market expansion. The firm maintained a strong adjusted gross profit margin of 77%, an increase of 110 basis points from the previous year. Analysts from various firms have noted the company’s strong performance, particularly in the broker channel, which contributed significantly to growth. The company also highlighted its continued investment in AI and product innovation as key factors in its success. Looking forward, Paylocity projects recurring revenue between $1.460 billion and $1.465 billion for the full fiscal year 2025, representing a 14% growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.